Discovering Bank First And 2 More Stocks That May Be Trading Below Their Estimated Value

As the U.S. stock market navigates through the complexities of a government shutdown and fluctuating economic indicators, major indices like the Dow Jones and S&P 500 have shown resilience with recent gains. In this environment, identifying stocks that may be trading below their estimated value can offer potential opportunities for investors seeking to capitalize on market inefficiencies.

Advertisement

Top 10 Undervalued Stocks Based On Cash Flows In The United States

NameCurrent PriceFair Value (Est)Discount (Est)
Udemy (UDMY)$6.76$13.4349.7%
SLM (SLM)$27.55$53.6548.6%
Perfect (PERF)$1.88$3.6348.2%
Investar Holding (ISTR)$22.83$45.2949.6%
Hess Midstream (HESM)$34.41$66.7848.5%
HCI Group (HCI)$193.48$376.1348.6%
First Commonwealth Financial (FCF)$16.81$32.9749%
First Busey (BUSE)$23.17$45.3048.8%
Alnylam Pharmaceuticals (ALNY)$456.35$884.8148.4%
AGNC Investment (AGNC)$10.06$19.3648%

Click here to see the full list of 201 stocks from our Undervalued US Stocks Based On Cash Flows screener.

We're going to check out a few of the best picks from our screener tool.

Bank First (BFC)

Overview: Bank First Corporation, with a market cap of $1.26 billion, operates as a holding company for Bank First, N.A., providing various banking services.

Operations: The company generates revenue primarily through its banking operations, amounting to $166 million.

Estimated Discount To Fair Value: 10.6%

Bank First is trading at US$128.34, below its estimated fair value of US$143.63, indicating it may be undervalued based on cash flows. The company's earnings and revenue are forecast to grow significantly faster than the US market over the next three years, with earnings expected to increase by 33.13% annually. Recent financial results show improved net interest income and net income compared to last year, alongside a share buyback program enhancing shareholder value.

BFC Discounted Cash Flow as at Oct 2025
BFC Discounted Cash Flow as at Oct 2025

BioLife Solutions (BLFS)

Overview: BioLife Solutions, Inc. develops, manufactures, and markets bioproduction products and services for the cell and gene therapy industry across various regions, with a market cap of approximately $1.27 billion.

Operations: The company's revenue is primarily derived from its Biopreservation Tools segment, which generated $93.47 million.

Estimated Discount To Fair Value: 37.3%

BioLife Solutions, trading at US$26.59, is significantly below its estimated fair value of US$42.4, highlighting its potential undervaluation based on cash flows. Despite recent insider selling, the company forecasts revenue growth faster than the US market and expects to become profitable within three years. Recent earnings guidance was revised upward for 2025, reflecting strong performance in their Cell Processing platform with expected revenue growth between 22% and 25% compared to last year.

BLFS Discounted Cash Flow as at Oct 2025
BLFS Discounted Cash Flow as at Oct 2025

Palomar Holdings (PLMR)

Overview: Palomar Holdings, Inc. is a specialty insurance company offering property and casualty insurance to individuals and businesses in the United States, with a market cap of approximately $3.12 billion.

Operations: The company generates revenue of $682.21 million from its property and casualty insurance business in the United States.

Estimated Discount To Fair Value: 44.6%

Palomar Holdings, priced at US$116.57, is trading significantly below its estimated fair value of US$210.53, suggesting potential undervaluation based on cash flows. Recent earnings reports show robust growth with Q2 revenue reaching US$203.31 million and net income at US$46.53 million, both up from last year. Despite substantial insider selling recently, the company forecasts annual revenue growth of 21%, outpacing the broader market's 9.8% projection.

PLMR Discounted Cash Flow as at Oct 2025
PLMR Discounted Cash Flow as at Oct 2025

Where To Now?

Looking For Alternative Opportunities?

This article by Simply Wall St is general in nature. We provide commentary based on historical data and analyst forecasts only using an unbiased methodology and our articles are not intended to be financial advice. It does not constitute a recommendation to buy or sell any stock, and does not take account of your objectives, or your financial situation. We aim to bring you long-term focused analysis driven by fundamental data. Note that our analysis may not factor in the latest price-sensitive company announcements or qualitative material. Simply Wall St has no position in any stocks mentioned.

Valuation is complex, but we're here to simplify it.

Discover if BioLife Solutions might be undervalued or overvalued with our detailed analysis, featuring fair value estimates, potential risks, dividends, insider trades, and its financial condition.

Access Free Analysis

Have feedback on this article? Concerned about the content? Get in touch with us directly. Alternatively, email editorial-team@simplywallst.com

About NasdaqCM:BLFS

BioLife Solutions

Develops, manufactures, and markets bioproduction products and services for the cell and gene therapy (CGT) industry in the United States, Europe, the Middle East, Africa, and internationally.

Flawless balance sheet with reasonable growth potential.

Advertisement

Weekly Picks

LO
Lou_Basenese
VTIX logo
Lou_Basenese on Virtuix Holdings ·

From a “Shark Tank” Snub to an Air Force “Yes”: Why Virtuix at $3.50 May Be the Market’s Most Mispriced AI Story

Fair Value:US$7.563.6% undervalued
31 users have followed this narrative
0 users have commented on this narrative
6 users have liked this narrative
IN
Investingwilly
MA logo
Investingwilly on Mastercard ·

Mastercard: The Best Dividend Stock You're Ignoring

Fair Value:US$75032.0% undervalued
77 users have followed this narrative
1 users have commented on this narrative
9 users have liked this narrative
TR
tripledub
INTU logo
tripledub on Intuit ·

A Wonderful Business at a Not-So-Wonderful Price

Fair Value:US$56052.4% undervalued
66 users have followed this narrative
4 users have commented on this narrative
31 users have liked this narrative
TA
Talos
HYFT logo
Talos on MindWalk Holdings ·

The Asymmetric TechBio Play: MindWalk Holdings and the Valuation Disconnect

Fair Value:US$8.2779.9% undervalued
36 users have followed this narrative
0 users have commented on this narrative
9 users have liked this narrative

Updated Narratives

RO
RockeTeller
AMQ logo
RockeTeller on Abitibi Metals ·

Abitibi Metals’ High-Grade B26 Polymetallic Deposit Trading at a Fraction of Peers, 96% Undervalued?

Fair Value:CA$1.2950.4% undervalued
4 users have followed this narrative
0 users have commented on this narrative
1 users have liked this narrative
EV
2190 logo
everyseed on Zylox-Tonbridge Medical Technology ·

Zylox-Tonbridge: Early Signs of an Emerging Global Vascular Intervention Platform

Fair Value:HK$30.8539.9% undervalued
2 users have followed this narrative
0 users have commented on this narrative
0 users have liked this narrative
AN
GEOHAN logo
Anthony_Lee on Geohan Corporation Berhad ·

Geohan's Growth Outlook Brightens on Expanding Order Book and Easing Cost Pressures

Fair Value:RM 0.7460.8% undervalued
3 users have followed this narrative
0 users have commented on this narrative
0 users have liked this narrative

Popular Narratives

IN
Investingwilly
MA logo
Investingwilly on Mastercard ·

Mastercard: The Best Dividend Stock You're Ignoring

Fair Value:US$75032.0% undervalued
77 users have followed this narrative
1 users have commented on this narrative
9 users have liked this narrative
HA
HarishPK
ADBE logo
HarishPK on Adobe ·

Adobe: A Probabilistic Case for Undervaluation

Fair Value:US$319.9635.5% undervalued
62 users have followed this narrative
9 users have commented on this narrative
19 users have liked this narrative
MA
martinarauz
NU logo
martinarauz on Nu Holdings ·

Investment Analysis (May 2026)

Fair Value:US$22.7442.3% undervalued
68 users have followed this narrative
0 users have commented on this narrative
17 users have liked this narrative